By Karen Roman
SkylineDx said its Merlin CP-GEP molecular test identifies a subset of T1a melanoma patients with sentinel lymph node (SLN) positivity above guideline thresholds.
The National Comprehensive Cancer Network updated its guidelines recognizing the Merlin CP-GEP as the only predictive genomic test used to guide SLNB decisions, the company stated.
“CP-GEP identified a subset of T1a patients with SLN positivity above guideline thresholds (>10%), enabling actionable risk stratification,” said Dr. Wesley Yu, et al., authors of the study. “A high-risk Merlin CP-GEP result may serve as an additional adverse feature when considering SLNB in T1a melanoma.”
READ MORE
Tech Edge Arrives at RSA Conference 2026 with Cloudflare, Rapid7, Radware
Never Miss our Weekly Highlights HERE
